Source
Longevity Technology
Fresh funding backs a high-stakes attempt to do what current amyloidosis drugs still cannot: clear the buildup already damaging the heart.
UK-based biotech Immutrin has raised $87 million (£65 million) in an oversubscribed Series A round to push forward a next-generation antibody therapy aimed at a stubborn gap in amyloidosis treatment: removing the harmful protein buildup already lodged in patients’ tissues.
News Url